Text this: Effectiveness and safety of BCD180, anti-TRBV9⁺ T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA